163 related articles for article (PubMed ID: 36449764)
21. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters.
Pirwany IR; Fleming R; Greer IA; Packard CJ; Sattar N
Clin Endocrinol (Oxf); 2001 Apr; 54(4):447-53. PubMed ID: 11318779
[TBL] [Abstract][Full Text] [Related]
22. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
Kriplani A; Periyasamy AJ; Agarwal N; Kulshrestha V; Kumar A; Ammini AC
Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
[TBL] [Abstract][Full Text] [Related]
23. The effects of behavioral intervention on anthropometric, clinical, and biochemical parameters in patients with polycystic ovary syndrome: a systematic review and meta-analysis.
Xie M; Yang Y; Zhang J
Front Endocrinol (Lausanne); 2024; 15():1297841. PubMed ID: 38481448
[TBL] [Abstract][Full Text] [Related]
24. Evidence of heterogeneous mechanisms in lipoprotein lipid alterations in hyperandrogenic women.
Wild RA; Bartholomew M; Applebaum-Bowden D; Demers LM; Hazzard W; Santen RJ
Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 1):1998-2005. PubMed ID: 2256513
[TBL] [Abstract][Full Text] [Related]
25. Clinical and laboratory features in women with different phenotypes of polycystic ovary syndrome.
Safari A; Mosadeghkhah A; Khameneie MK
Minerva Obstet Gynecol; 2024 Feb; 76(1):27-35. PubMed ID: 35912463
[TBL] [Abstract][Full Text] [Related]
26. [Obesity, hormonal and metabolic abnormalities in adolescent girls with polycystic ovary syndrome].
Ságodi L; Lombay B; Vámosi I; Barkai L
Orv Hetil; 2013 Aug; 154(31):1226-34. PubMed ID: 23895991
[TBL] [Abstract][Full Text] [Related]
27. Hyperandrogenemia in polycystic ovary syndrome: exploration of the role of free testosterone and androstenedione in metabolic phenotype.
Lerchbaum E; Schwetz V; Rabe T; Giuliani A; Obermayer-Pietsch B
PLoS One; 2014; 9(10):e108263. PubMed ID: 25310562
[TBL] [Abstract][Full Text] [Related]
28. Study on the Effect of Berberine, Myoinositol, and Metformin in Women with Polycystic Ovary Syndrome: A Prospective Randomised Study.
Mishra N; Verma R; Jadaun P
Cureus; 2022 Jan; 14(1):e21781. PubMed ID: 35251851
[TBL] [Abstract][Full Text] [Related]
29. Clinical and biochemical presentation of polycystic ovary syndrome in women between the ages of 20 and 40.
Liang SJ; Hsu CS; Tzeng CR; Chen CH; Hsu MI
Hum Reprod; 2011 Dec; 26(12):3443-9. PubMed ID: 21926412
[TBL] [Abstract][Full Text] [Related]
30. [Activity and distribution of plasma platelet-activating factor acetylhydrolase in polycystic ovary syndrome patients with insulin resistance].
Wan DH; Fan P; Bai H; Song Q; Liu HW
Zhonghua Fu Chan Ke Za Zhi; 2010 Jan; 45(1):30-4. PubMed ID: 20367923
[TBL] [Abstract][Full Text] [Related]
31. Oxidised low-density lipoprotein concentration - early marker of an altered lipid metabolism in young women with PCOS.
Macut D; Damjanovic S; Panidis D; Spanos N; Glisic B; Petakov M; Rousso D; Kourtis A; Bjekic J; Milic N
Eur J Endocrinol; 2006 Jul; 155(1):131-6. PubMed ID: 16793959
[TBL] [Abstract][Full Text] [Related]
32. Circulating levels of obestatin and copeptin in obese and nonobese women with polycystic ovary syndrome.
Taskin MI; Bulbul E; Adali E; Hismiogulları AA; Inceboz U
Eur J Obstet Gynecol Reprod Biol; 2015 Jun; 189():19-23. PubMed ID: 25837320
[TBL] [Abstract][Full Text] [Related]
33. Endotrophin as a novel marker in PCOS and its relation with other adipokines and metabolic parameters: a pilot study.
Guney G; Taskin MI; Baykan O; Adali E; Gul Tezcan S; Sarikaya S; Kaya C; Tolu E
Ther Adv Endocrinol Metab; 2021; 12():20420188211049607. PubMed ID: 34659735
[TBL] [Abstract][Full Text] [Related]
34. A study on lipoprotein-a and PAI-1 in women with polycystic ovary syndrome.
Shah AK; Yadav BK; Suri A; Shah AK
Horm Mol Biol Clin Investig; 2022 Sep; 43(3):357-361. PubMed ID: 35439403
[TBL] [Abstract][Full Text] [Related]
35. [Effects of resolving method of Chinese medicine on the lipid metabolism in polycystic ovary syndrome accompanied with non-alcoholic fatty liver disease].
Chen Y; Wang XJ; Jin HL; Jin L
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jun; 33(6):751-6. PubMed ID: 23980352
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneity of Endocrinologic and Metabolic Parameters in Reproductive Age Polycystic Ovary Syndrome (PCOS) Women Concerning the Severity of Hyperandrogenemia-A New Insight on Syndrome Pathogenesis.
Ozegowska K; Korman M; Szmyt A; Pawelczyk L
Int J Environ Res Public Health; 2020 Dec; 17(24):. PubMed ID: 33322590
[TBL] [Abstract][Full Text] [Related]
37. [Monocyte chemoattractant protein-1 and its correlation with lipoprotein in polycystic ovary syndrome].
Hu WH; Qiao J; Zhao SY; Zhang XW; Li MZ
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):487-91. PubMed ID: 17068620
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of biochemical, endocrine, and metabolic biomarkers for the early diagnosis of polycystic ovary syndrome among non-obese Saudi women.
Daghestani MH
Int J Gynaecol Obstet; 2018 Aug; 142(2):162-169. PubMed ID: 29745981
[TBL] [Abstract][Full Text] [Related]
39. Triglycerides to High-Density Lipoprotein Cholesterol Ratio Can Predict Impaired Glucose Tolerance in Young Women with Polycystic Ovary Syndrome.
Song do K; Lee H; Sung YA; Oh JY
Yonsei Med J; 2016 Nov; 57(6):1404-11. PubMed ID: 27593868
[TBL] [Abstract][Full Text] [Related]
40. Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome.
Sabuncu T; Harma M; Harma M; Nazligul Y; Kilic F
Fertil Steril; 2003 Nov; 80(5):1199-204. PubMed ID: 14607575
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
